Direct oral anticoagulants in sickle cell disease: a systematic review and meta-analysis

Rozi, Waail; Rahhal, Alaa; Ali, Elrazi; Al-Mashdali, Abdulrahman F; Hilan, Yousef; Khamees, Ibrahim; Fernyhough, Liam; Yassin, Mohamed A

doi:10.1182/bloodadvances.2022007308

Cited by 6 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Extensive preclinical and clinical trial data have demonstrated that DOACs offer several advantages over traditional anticoagulants, such as warfarin, including predictable pharmacokinetics, rapid onset of action, and fewer drug-drug interactions [2,3]. DOACs have been shown to be effective in preventing and treating venous thromboembolism, as well as reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation [4,5]. In addition, DOACs have been found to be safe and well-tolerated, with a lower incidence of major bleeding events compared to traditional anticoagulants.…”

Section: Introductionmentioning

confidence: 99%

Antiplatelet Aggregation Properties of Cirsilineol: A Novel Inhibitor of Blood Coagulation Factor Xa

et al. 2023

View full text Add to dashboard Cite

A small natural substance called cirsilineol (CSL), which was discovered in the plant Artemisia vestita, is lethal to many cancer cells and has antioxidant, anticancer, and antibacterial properties. Here, we investigated the underlying mechanisms of the antithrombotic action of CSL. We demonstrated that CSL has antithrombotic efficacy comparable to rivaroxaban, a direct blood coagulation factor Xa (FXa) inhibitor employed as a positive control, in inhibiting the enzymatic activity of FXa and the platelet aggregation induced by adenosine diphosphate (ADP) and U46619, a thromboxane A2 analog. The expression of P-selectin, the phosphorylation of myristoylated alanine-rich C kinase substrate by U46619 or ADP, and the activation of PAC-1 in platelets were inhibited by CSL. Nitric oxide production was increased by CSL in ADP- or U46619-treated human umbilical vein endothelial cells (HUVECs), although excessive endothelin-1 secretion was suppressed. CSL demonstrated strong anticoagulant and antithrombotic effects in a mouse model of arterial and pulmonary thrombosis. Our findings suggest that CSL is a potential pharmacological candidate for a novel class of anti-FXa and antiplatelet medications.

show abstract

Section: Introductionmentioning

confidence: 99%

Antiplatelet Aggregation Properties of Cirsilineol: A Novel Inhibitor of Blood Coagulation Factor Xa

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Moreover, there are multiple treatment options that may be of benefit but remain unproven due to the lack of sufficient evidence. Options include Apligraf (a skin equivalent), hyperbaric oxygen, RGD peptide matrix, topical timolol, topical sodium nitrite cream, topical triple anti-biotherapy, solcoseryl, and collagen/glycosaminoglycan matrix (7,13). The role of novel sickle cell disease drugs in the management of leg ulcers is not yet clear (14)(15)(16).…”

Section: Discussionmentioning

confidence: 99%

Sickle cell leg ulcer successfully managed by hyperbaric oxygen: a case report

et al. 2023

Self Cite

View full text Add to dashboard Cite

Sickle cell leg ulcers (SCLUs) are usually chronic, painful, and devastating complications of sickle cell disease. Skin vaso-occlusion with compromised blood flow, chronic inflammation, and endothelial dysfunction is thought to be the underlying mechanism. It is usually slow to heal, and it may become chronic and superinfected. The management of SCLUs is usually challenging and requires a multidisciplinary team. Multiple systemic and local therapies have been tried in SCLU treatment. However, the outcome is variable: currently, there are no official recommendations for the best effective treatment. Herein, we report a 34-year-old male patient with non-transfusion-dependent sickle cell disease who was suffering from a chronic left ankle ulcer and was successfully managed with hyperbaric oxygen therapy, resulting in a complete resolution of this devastating complication.

show abstract

“…The hallmarks of SCD are recurrent vaso‐occlusive crises and hemolytic anemia. Vaso‐occlusive crises manifest as acute pain crises, acute chest syndrome, and priapism—they are mainly caused by obstructions of the microcirculation and lead to tissue hypoxia and severe pain 1–3 …”

Section: Introductionmentioning

confidence: 99%

“…Vasoocclusive crises manifest as acute pain crises, acute chest syndrome, and priapism-they are mainly caused by obstructions of the microcirculation and lead to tissue hypoxia and severe pain. [1][2][3] Priapism is defined as a persistent erection of the penis that is not associated with sexual interest or desire. It can occur with low flow (ischemic and vaso-occlusive) or high flow (non-ischemic).…”

Section: Introductionmentioning

confidence: 99%

Potential efficacy of crizanlizumab in treating priapism in sickle cell disease: A case report

Abdulgayoom,

Afana,

Alshurafa

et al. 2024

Clinical Case Reports

Self Cite

View full text Add to dashboard Cite

Key Clinical MessageThis report documents the treatment of a 41‐year‐old male with sickle cell disease (SCD) and repeated stuttering priapism using crizanlizumab, which alleviated the priapism but induced a significant vaso‐occlusive crisis during the second infusion. Encouragingly, no subsequent vaso‐occlusive crises occurred. However, the potential for infusion‐related adverse events warrants close supervision. Further research is necessary to explore its full benefits on priapism management.

show abstract

Direct oral anticoagulants in sickle cell disease: a systematic review and meta-analysis

Cited by 6 publications

References 32 publications

Antiplatelet Aggregation Properties of Cirsilineol: A Novel Inhibitor of Blood Coagulation Factor Xa

Antiplatelet Aggregation Properties of Cirsilineol: A Novel Inhibitor of Blood Coagulation Factor Xa

Sickle cell leg ulcer successfully managed by hyperbaric oxygen: a case report

Potential efficacy of crizanlizumab in treating priapism in sickle cell disease: A case report

Contact Info

Product

Resources

About